Oregovomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Oregovomab
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CA125
Clinical data
Trade names OvaRex
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Molar mass ca. 150 kg/mol
 NYesY (what is this?)  (verify)

Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer.[1]

This drug was developed by AltaRex Corp.

Adverse drug effects[edit]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oregovomab, American Medical Association.